Finanzen von Sagimet Biosciences Inc (SGMT)SGMTSagimet Biosciences Inc

Evaluating the bottom line, Sagimet Biosciences Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -24.37%, provide a clear picture of how effectively SGMT converts its operational activities into shareholder value.

In the context of the broader market, SGMT competes directly with industry leaders such as PHAT and OLMA. With a market capitalization of $690.65M, it holds a leading position in the sector. When comparing efficiency, SGMT's gross margin of N/A stands against PHAT's 79.68% and OLMA's N/A. Such benchmarking helps identify whether Sagimet Biosciences Inc. is trading at a premium or discount relative to its financial performance.

Sagimet has reported consistent net losses, with Q2 2026 showing a net income loss of $13.95 million and a negative EPS of -0.26, reflecting ongoing financial challenges.